Ravidasvir free base is primarily used in the treatment of chronic hepatitis C virus (HCV) infections. It is often administered in combination with other antiviral agents, such as sofosbuvir, to enhance its efficacy. This combination therapy targets different stages of the HCV lifecycle, reducing the viral load and improving patient outcomes. Ravidasvir is particularly effective across multiple HCV genotypes, making it a versatile option in regions with diverse HCV strains. Its use has shown promising results in achieving sustained virological response (SVR), which is a key indicator of successful treatment. Additionally, it is being explored in clinical trials for its potential in treating other viral infections, expanding its therapeutic applications.